Docteur Sarah PAYET

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• MEDECINE DU TRAVAIL DE REGION MARCOULE

  ZONE D'ACCUEIL — CHEMIN VIEUX DE CHUSCLAN, 30200 Chusclan

  Hospitalier
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Elderly-onset rheumatoid arthritis

  Joint bone spine · 2010

  📚 40 citations🎯 RCR 1.18
• 2

  Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry

  Arthritis care & research · 2014

  📚 33 citations🎯 RCR 1.33

  Lire l'abstract Crossref ↓

  ObjectiveThe aim of this study was to compare the efficacy and safety of rituximab (RTX) as a function of patient age.MethodsWe included all rheumatoid arthritis patients in the AutoImmunity and Rituximab registry with a 2‐year followup.ResultsOf the 1,709 patients, 191 were age ≥75 years, 417 were ages 65–74 years, 907 were ages 50–64 years, and 194 were age <50 years. At baseline, the elderly and very elderly patients presented with longer disease duration, a higher incidence of erythrocyte sedimentation rate and C‐reactive protein level, a lower incidence of previous tumor necrosis factor α (TNFα) therapy, and a smaller number of previously used TNFα agents. Disease activity, rheumatoid factor (RF), or anti–cyclic citrullinated peptide (anti‐CCP) antibodies and corticosteroid therapy were not statistically different among the groups. At 24 months, no significant difference was shown among the groups for RTX discontinuation rates (36.1% if age <50 years, 32.6% if ages 50–64 years, 34.5% if ages 65–74 years, and 32.5% if age >75 years). The reasons for discontinuation (inefficacy, adverse events) were the same in all 4 groups. Infections were more common in the elderly. Patients ages 65–75 years were more likely to be good responders than nonresponders at 1 year of followup than patients age ≥75 years (odds ratio 3.81, 95% confidence interval 1.14–12.79) after adjustment on disease duration, RF/anti‐CCP positivity, corticosteroids, anti‐TNF use, and baseline Disease Activity Score in 28 joints (DAS28). After the sixth month, the decrease in DAS28 score was less marked in the population age >75 years than in the group age <50 years.ConclusionThe efficacy and safety of RTX is affected by age.

• 3

  Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis

  Joint bone spine · 2008

  📚 21 citations

Publications scientifiques (6) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche